Symbols / ARQT Stock $21.60 +0.14% Arcutis Biotherapeutics, Inc.
ARQT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-07 | reit | Needham | Buy → Buy | $36 |
| 2026-03-02 | main | Mizuho | Outperform → Outperform | $35 |
| 2026-02-27 | main | Guggenheim | Buy → Buy | $35 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $35 |
| 2026-02-26 | main | HC Wainwright & Co. | Buy → Buy | $34 |
| 2026-02-26 | main | Needham | Buy → Buy | $36 |
| 2026-01-26 | main | Needham | Buy → Buy | $31 |
| 2025-11-28 | main | Mizuho | Outperform → Outperform | $37 |
| 2025-10-30 | main | Goldman Sachs | Neutral → Neutral | $29 |
| 2025-10-28 | main | Needham | Buy → Buy | $30 |
| 2025-08-07 | main | Needham | Buy → Buy | $22 |
| 2025-07-25 | init | Goldman Sachs | — → Neutral | $18 |
| 2025-05-23 | reit | Needham | Buy → Buy | $20 |
| 2025-04-09 | reit | Needham | Buy → Buy | $20 |
| 2025-04-03 | reit | Guggenheim | Buy → Buy | — |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-04-03 | reit | Needham | Buy → Buy | $20 |
| 2025-03-11 | main | Jefferies | Buy → Buy | $19 |
| 2025-02-27 | main | Goldman Sachs | Neutral → Neutral | $15 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
- Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha Fri, 15 May 2026 11
- Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView Fri, 15 May 2026 12
- ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill ue, 12 May 2026 07
- Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan Wed, 13 May 2026 23
- Arcutis Biotherapeutics, Inc. - Common stock (NQ: ARQT - FinancialContent Fri, 15 May 2026 03
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After Q1 2026 Results And ZORYVE Label Expansion Efforts - simplywall.st Mon, 11 May 2026 04
- Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN hu, 14 May 2026 11
- ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings - Quiver Quantitative Wed, 06 May 2026 20
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Yahoo Finance hu, 23 Apr 2026 07
- Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan Wed, 13 May 2026 23
- Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Reaffirming 2026 Guidance And Advancing ZORYVE sNDA - simplywall.st Sat, 09 May 2026 12
- Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback - Yahoo Finance Sun, 25 Jan 2026 08
- State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan ue, 12 May 2026 13
- Arcutis Biotherapeutics (ARQT) Form 144: Patrick Burnett reports share dispositions - Stock Titan Mon, 11 May 2026 20
- Arcutis Biotherapeutics (ARQT) Form 144 lists 435 vested shares for resale - Stock Titan Mon, 11 May 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
376.07
+91.34%
|
196.54
+229.74%
|
59.61
+1517.09%
|
3.69
|
| Operating Revenue |
|
372.07
+123.41%
|
166.54
+470.62%
|
29.19
+691.81%
|
3.69
|
| Cost Of Revenue |
|
36.70
+91.84%
|
19.13
+283.56%
|
4.99
+561.41%
|
0.75
|
| Reconciled Cost Of Revenue |
|
36.70
+91.84%
|
19.13
+283.56%
|
4.99
+561.41%
|
0.75
|
| Gross Profit |
|
339.38
+91.29%
|
177.41
+224.82%
|
54.62
+1762.86%
|
2.93
|
| Operating Expense |
|
351.60
+14.97%
|
305.81
+3.41%
|
295.72
-2.90%
|
304.56
|
| Research And Development |
|
77.05
+0.83%
|
76.42
-30.89%
|
110.58
-39.39%
|
182.44
|
| Selling General And Administration |
|
274.55
+19.69%
|
229.39
+23.90%
|
185.15
+51.60%
|
122.12
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Other Gand A |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
388.30
+19.50%
|
324.94
+8.06%
|
300.71
-1.51%
|
305.31
|
| Operating Income |
|
-12.23
+90.48%
|
-128.40
+46.75%
|
-241.10
+20.07%
|
-301.63
|
| Total Operating Income As Reported |
|
-12.23
+90.48%
|
-128.40
+46.75%
|
-241.10
+20.07%
|
-301.63
|
| EBITDA |
|
1.78
+101.61%
|
-110.27
+51.76%
|
-228.56
+22.49%
|
-294.87
|
| Normalized EBITDA |
|
1.78
+101.61%
|
-110.27
+51.76%
|
-228.56
+22.49%
|
-294.87
|
| Reconciled Depreciation |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| EBIT |
|
-2.89
+97.43%
|
-112.22
+51.06%
|
-229.31
+22.48%
|
-295.81
|
| Net Income |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Pretax Income |
|
-14.97
+89.26%
|
-139.39
+46.19%
|
-259.03
+16.83%
|
-311.46
|
| Net Non Operating Interest Income Expense |
|
-3.19
+71.15%
|
-11.04
+35.78%
|
-17.20
-9.86%
|
-15.65
|
| Interest Expense Non Operating |
|
12.08
-55.52%
|
27.17
-8.56%
|
29.71
+89.83%
|
15.65
|
| Net Interest Income |
|
-3.19
+71.15%
|
-11.04
+35.78%
|
-17.20
-9.86%
|
-15.65
|
| Interest Expense |
|
12.08
-55.52%
|
27.17
-8.56%
|
29.71
+89.83%
|
15.65
|
| Interest Income Non Operating |
|
8.90
-44.83%
|
16.13
+28.83%
|
12.52
|
—
|
| Interest Income |
|
8.90
-44.83%
|
16.13
+28.83%
|
12.52
|
—
|
| Other Income Expense |
|
0.44
+842.55%
|
0.05
+106.43%
|
-0.73
-112.56%
|
5.82
|
| Other Non Operating Income Expenses |
|
0.44
+842.55%
|
0.05
+106.43%
|
-0.73
-112.56%
|
5.82
|
| Tax Provision |
|
1.17
+80.99%
|
0.65
-79.22%
|
3.11
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income From Continuing Operation Net Minority Interest |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income From Continuing And Discontinued Operation |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income Continuous Operations |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Normalized Income |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income Common Stockholders |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Diluted EPS |
|
-0.13
+88.79%
|
-1.16
+69.31%
|
-3.78
+33.22%
|
-5.66
|
| Basic EPS |
|
-0.13
+88.79%
|
-1.16
+69.31%
|
-3.78
+33.22%
|
-5.66
|
| Basic Average Shares |
|
127.23
+5.19%
|
120.96
+74.53%
|
69.31
+25.94%
|
55.03
|
| Diluted Average Shares |
|
127.23
+5.19%
|
120.96
+74.53%
|
69.31
+25.94%
|
55.03
|
| Diluted NI Availto Com Stockholders |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
432.97
+24.10%
|
348.89
+2.20%
|
341.37
-24.02%
|
449.27
|
| Current Assets |
|
411.23
+22.46%
|
335.82
+1.63%
|
330.43
-24.46%
|
437.41
|
| Cash Cash Equivalents And Short Term Investments |
|
220.98
-3.06%
|
227.96
-16.15%
|
271.86
-33.63%
|
409.59
|
| Cash And Cash Equivalents |
|
42.91
-39.85%
|
71.33
-19.30%
|
88.40
+64.80%
|
53.64
|
| Cash Equivalents |
|
42.91
-39.85%
|
71.33
-19.30%
|
88.40
+64.80%
|
53.64
|
| Other Short Term Investments |
|
178.07
+13.70%
|
156.62
-14.63%
|
183.46
-48.46%
|
355.95
|
| Receivables |
|
146.23
+100.13%
|
73.07
+183.12%
|
25.81
+205.12%
|
8.46
|
| Accounts Receivable |
|
146.23
+100.13%
|
73.07
+183.12%
|
25.81
+205.12%
|
8.46
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Inventory |
|
22.63
+55.82%
|
14.53
+10.60%
|
13.13
+74.79%
|
7.51
|
| Raw Materials |
|
5.05
+17.37%
|
4.30
-56.79%
|
9.95
+75.84%
|
5.66
|
| Work In Process |
|
5.03
+761.82%
|
0.58
+20.16%
|
0.49
+23.04%
|
0.40
|
| Finished Goods |
|
12.55
+30.20%
|
9.64
+257.51%
|
2.70
+84.73%
|
1.46
|
| Prepaid Assets |
|
12.06
+13.65%
|
10.61
+1.11%
|
10.50
+141.07%
|
4.35
|
| Restricted Cash |
|
0.31
-50.08%
|
0.62
-33.30%
|
0.93
-25.04%
|
1.23
|
| Other Current Assets |
|
9.02
-0.29%
|
9.04
+10.17%
|
8.21
+31.18%
|
6.26
|
| Total Non Current Assets |
|
21.74
+66.36%
|
13.07
+19.53%
|
10.93
-7.87%
|
11.87
|
| Net PPE |
|
5.51
+84.03%
|
2.99
-23.23%
|
3.90
-15.25%
|
4.60
|
| Gross PPE |
|
8.76
+57.57%
|
5.56
-4.57%
|
5.82
+1.20%
|
5.75
|
| Accumulated Depreciation |
|
-3.25
-26.68%
|
-2.56
-33.26%
|
-1.92
-66.87%
|
-1.15
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
2.72
+33.68%
|
2.04
+7.49%
|
1.90
+29.26%
|
1.47
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
4.47
+128.73%
|
1.95
-17.28%
|
2.36
-13.23%
|
2.72
|
| Leases |
|
1.57
+0.00%
|
1.57
+0.00%
|
1.57
+0.00%
|
1.57
|
| Goodwill And Other Intangible Assets |
|
14.81
+56.26%
|
9.48
+47.24%
|
6.44
-10.43%
|
7.19
|
| Other Non Current Assets |
|
1.42
+138.09%
|
0.60
+0.00%
|
0.60
+664.10%
|
0.08
|
| Total Liabilities Net Minority Interest |
|
243.49
+27.25%
|
191.35
-24.28%
|
252.70
+5.43%
|
239.69
|
| Current Liabilities |
|
129.84
+60.27%
|
81.01
+73.59%
|
46.67
+23.44%
|
37.81
|
| Payables And Accrued Expenses |
|
108.31
+79.71%
|
60.27
+94.02%
|
31.06
+34.17%
|
23.15
|
| Payables |
|
12.53
-11.90%
|
14.22
+18.58%
|
11.99
+35.86%
|
8.83
|
| Accounts Payable |
|
12.53
-11.90%
|
14.22
+18.58%
|
11.99
+35.86%
|
8.83
|
| Current Accrued Expenses |
|
95.78
+108.00%
|
46.05
+141.47%
|
19.07
+33.14%
|
14.32
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
20.53
-1.03%
|
20.75
+39.50%
|
14.87
+6.23%
|
14.00
|
| Current Debt And Capital Lease Obligation |
|
1.00
+21.95%
|
0.82
+11.56%
|
0.73
+11.87%
|
0.66
|
| Current Debt |
|
1.00
|
—
|
—
|
—
|
| Other Current Borrowings |
|
1.00
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.82
+11.56%
|
0.73
+11.87%
|
0.66
|
| Total Non Current Liabilities Net Minority Interest |
|
113.66
+3.01%
|
110.33
-46.45%
|
206.03
+2.05%
|
201.89
|
| Long Term Debt And Capital Lease Obligation |
|
113.22
+3.15%
|
109.77
-46.50%
|
205.18
+1.63%
|
201.89
|
| Long Term Debt |
|
107.96
+0.71%
|
107.20
-46.88%
|
201.80
+2.04%
|
197.77
|
| Long Term Capital Lease Obligation |
|
5.27
+105.54%
|
2.56
-24.25%
|
3.38
-17.85%
|
4.12
|
| Other Non Current Liabilities |
|
0.43
-24.39%
|
0.57
-32.86%
|
0.85
|
—
|
| Stockholders Equity |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Common Stock Equity |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+33.33%
|
0.01
+50.00%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+33.33%
|
0.01
+50.00%
|
0.01
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
123.33
+4.65%
|
117.85
+21.76%
|
96.79
+58.57%
|
61.04
|
| Ordinary Shares Number |
|
123.33
+4.65%
|
117.85
+21.76%
|
96.79
+58.57%
|
61.04
|
| Additional Paid In Capital |
|
1,327.60
+3.76%
|
1,279.48
+19.52%
|
1,070.56
+15.06%
|
930.42
|
| Retained Earnings |
|
-1,138.08
-1.44%
|
-1,121.94
-14.26%
|
-981.90
-36.42%
|
-719.76
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.04
-528.57%
|
-0.01
-275.00%
|
0.00
+100.37%
|
-1.09
|
| Other Equity Adjustments |
|
-0.04
-528.57%
|
-0.01
-275.00%
|
0.00
+100.37%
|
-1.09
|
| Total Equity Gross Minority Interest |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Total Capitalization |
|
297.44
+12.35%
|
264.74
-8.86%
|
290.47
-28.69%
|
407.35
|
| Working Capital |
|
281.39
+10.43%
|
254.81
-10.20%
|
283.76
-28.99%
|
399.60
|
| Invested Capital |
|
298.44
+12.73%
|
264.74
-8.86%
|
290.47
-28.69%
|
407.35
|
| Total Debt |
|
114.22
+4.06%
|
109.77
-46.69%
|
205.92
+1.67%
|
202.54
|
| Net Debt |
|
66.05
+84.15%
|
35.87
-68.37%
|
113.40
-21.32%
|
144.13
|
| Capital Lease Obligations |
|
5.27
+105.54%
|
2.56
-37.77%
|
4.12
-13.76%
|
4.77
|
| Net Tangible Assets |
|
174.67
+17.97%
|
148.06
+80.06%
|
82.23
-59.37%
|
202.39
|
| Tangible Book Value |
|
174.67
+17.97%
|
148.06
+80.06%
|
82.23
-59.37%
|
202.39
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.62
+94.98%
|
-112.16
+54.60%
|
-247.06
+4.14%
|
-257.71
|
| Cash Flow From Continuing Operating Activities |
|
-5.62
+94.98%
|
-112.16
+54.60%
|
-247.06
+4.14%
|
-257.71
|
| Net Income From Continuing Operations |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Depreciation Amortization Depletion |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| Depreciation |
|
—
|
0.64
-16.99%
|
0.77
+23.95%
|
0.62
|
| Amortization Cash Flow |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
+140.38%
|
0.31
|
| Depreciation And Amortization |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| Amortization Of Intangibles |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
+140.38%
|
0.31
|
| Other Non Cash Items |
|
2.41
-60.99%
|
6.17
+2.71%
|
6.01
-81.54%
|
32.55
|
| Stock Based Compensation |
|
40.36
-3.27%
|
41.73
+7.52%
|
38.81
+18.76%
|
32.68
|
| Operating Gains Losses |
|
—
|
-0.28
-132.86%
|
0.85
|
—
|
| Gain Loss On Investment Securities |
|
—
|
-0.28
-132.86%
|
0.85
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
-34.83
-130.96%
|
-15.08
+35.83%
|
-23.50
-130.97%
|
-10.18
|
| Change In Receivables |
|
-73.16
-54.81%
|
-47.26
-172.40%
|
-17.35
-105.12%
|
-8.46
|
| Changes In Account Receivables |
|
-73.16
-54.81%
|
-47.26
-172.40%
|
-17.35
-105.12%
|
-8.46
|
| Change In Inventory |
|
-7.33
-1732.25%
|
-0.40
+92.88%
|
-5.62
+25.21%
|
-7.51
|
| Change In Prepaid Assets |
|
-2.01
-111.71%
|
-0.95
+89.00%
|
-8.62
-348.30%
|
3.47
|
| Change In Payables And Accrued Expense |
|
48.35
+41.12%
|
34.26
+291.74%
|
8.75
+217.11%
|
2.76
|
| Change In Accrued Expense |
|
50.04
+56.23%
|
32.03
+472.63%
|
5.59
+368.90%
|
1.19
|
| Change In Payable |
|
-1.69
-176.00%
|
2.23
-29.28%
|
3.15
+101.41%
|
1.56
|
| Change In Account Payable |
|
-1.69
-176.00%
|
2.23
-29.28%
|
3.15
+101.41%
|
1.56
|
| Change In Other Current Liabilities |
|
-0.68
+7.48%
|
-0.73
-11.87%
|
-0.66
-51.73%
|
-0.43
|
| Investing Cash Flow |
|
-30.25
-204.97%
|
28.82
-84.01%
|
180.23
+306.69%
|
-87.20
|
| Cash Flow From Continuing Investing Activities |
|
-30.25
-204.97%
|
28.82
-84.01%
|
180.23
+306.69%
|
-87.20
|
| Net PPE Purchase And Sale |
|
-0.69
-379.72%
|
-0.14
+66.59%
|
-0.43
-28.53%
|
-0.33
|
| Purchase Of PPE |
|
-0.69
-379.72%
|
-0.14
+66.59%
|
-0.43
-28.53%
|
-0.33
|
| Capital Expenditure |
|
-10.69
-107.78%
|
-5.14
-1101.64%
|
-0.43
+98.16%
|
-23.28
|
| Net Investment Purchase And Sale |
|
-19.57
-157.61%
|
33.96
-81.20%
|
180.66
+382.65%
|
-63.92
|
| Purchase Of Investment |
|
-246.99
+3.07%
|
-254.82
-12.83%
|
-225.84
+45.63%
|
-415.39
|
| Sale Of Investment |
|
227.42
-21.25%
|
288.78
-28.96%
|
406.50
+15.66%
|
351.47
|
| Net Intangibles Purchase And Sale |
|
-10.00
-100.00%
|
-5.00
|
0.00
+100.00%
|
-22.95
|
| Purchase Of Intangibles |
|
-10.00
-100.00%
|
-5.00
|
0.00
+100.00%
|
-22.95
|
| Financing Cash Flow |
|
6.97
-89.47%
|
66.20
-34.66%
|
101.32
-66.43%
|
301.80
|
| Cash Flow From Continuing Financing Activities |
|
6.97
-89.47%
|
66.20
-34.66%
|
101.32
-66.43%
|
301.80
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-100.00
|
0.00
-100.00%
|
125.00
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
125.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-100.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
125.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-100.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-100.00
|
0.00
-100.00%
|
125.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Proceeds From Stock Option Exercised |
|
6.97
+54.27%
|
4.52
+86.62%
|
2.42
-17.56%
|
2.94
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-2.19
|
| Changes In Cash |
|
-28.91
-68.68%
|
-17.14
-149.67%
|
34.50
+180.01%
|
-43.12
|
| Effect Of Exchange Rate Changes |
|
0.17
+171.49%
|
-0.23
-370.00%
|
-0.05
|
0.00
|
| Beginning Cash Position |
|
71.95
-19.45%
|
89.32
+62.78%
|
54.88
-44.00%
|
97.99
|
| End Cash Position |
|
43.22
-39.94%
|
71.95
-19.45%
|
89.32
+62.78%
|
54.88
|
| Free Cash Flow |
|
-16.31
+86.09%
|
-117.30
+52.60%
|
-247.49
+11.93%
|
-281.00
|
| Interest Paid Supplemental Data |
|
10.33
-53.50%
|
22.21
-12.72%
|
25.45
+101.37%
|
12.64
|
| Amortization Of Securities |
|
-2.09
+69.66%
|
-6.90
+1.26%
|
-6.99
-210.21%
|
-2.25
|
| Common Stock Issuance |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-13 View
- 42026-05-13 View
- 42026-05-06 View
- 42026-05-06 View
- 42026-05-06 View
- 42026-05-06 View
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
- 42026-05-05 View
- 42026-04-03 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 42026-02-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|